The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.
 
Abdul Hamid Bazarbachi
No Relationships to Disclose
 
Musa Yilmaz
No Relationships to Disclose
 
Farhad Ravandi
No Relationships to Disclose
 
Deborah A. Thomas
No Relationships to Disclose
 
Maria Khouri
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Rebecca S. Garris
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Takeda
Research Funding - Ambit BioSciences (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst)
 
Nicholas James Short
No Relationships to Disclose
 
Koji Sasaki
No Relationships to Disclose
 
Ghayas C. Issa
No Relationships to Disclose
 
Paul B. Koller
No Relationships to Disclose
 
Tapan M. Kadia
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Celgene; Sanofi
 
Srdan Verstovsek
No Relationships to Disclose
 
Naval Guastad Daver
No Relationships to Disclose
 
Nitin Jain
Honoraria - Adaptive Biotechnologies; ADC Therapeutics; Novartis; Novimmune; Pfizer; Pharmacyclics; SERVIER
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; Novartis; Novimmune; Pfizer; Pharmacyclics; SERVIER
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); SERVIER (Inst)
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Amgen Astellas BioPharma; Aptose Biosciences; Celgene; CLL Global Research Foundation; Eisai; GlaxoSmithKline; Janssen Oncology; Loxo; Pharmacyclics; Sunesis Pharmaceuticals; Vaniam Group
Research Funding - Acerta Pharma; Gilead Sciences; Pfizer; Pharmacyclics; ProNAI; Regeneron; TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer
Research Funding - Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)